chevron_left
Drugs to Watch 2026: Navigating the next wave of GLP‑1 evolution and beyond
Speakers
Discover the therapies reshaping the global obesity and metabolic disease market—and what sets tomorrow’s winners apart.
The global obesity and metabolic disease market is undergoing rapid transformation. As next‑generation therapies—from oral GLP‑1 agents to multi‑pathway hormonal agonists—push innovation beyond traditional approaches, pharmaceutical leaders face increasing pressure to differentiate, demonstrate real‑world effectiveness and meet payer expectations.
In this on‑demand webinar, Clarivate experts unveil insights from the Drugs to Watch 2026 report and take a deep dive into two of Eli Lilly’s most anticipated therapies—orforglipron and retatrutide.
What you’ll learn:
Explore how R&D, commercial and strategy leaders are navigating a fast‑moving and increasingly competitive obesity landscape, including:
- The rise of differentiated mechanisms—from oral GLP‑1s to dual‑ and triple‑hormone agonists
- Key innovations behind orforglipron and retatrutide, and what makes them stand out
- Where investors and pharma are placing their biggest metabolic bets
- Market forces that could slow or accelerate adoption, including payer access, real-world adherence and safety perceptions
- How to build a drug that becomes a future “Drug to Watch”, using data‑driven frameworks and competitive intelligence
